Last reviewed · How we verify
Semaglutide N
Semaglutide N is a Small molecule drug developed by Novo Nordisk A/S. It is currently in Phase 1 development.
Semaglutide is being studied for various conditions, including Type 2 Diabetes, Obesity, and Metabolic Syndrome, as per ClinicalTrials.gov. According to ClinicalTrials.gov and ChEMBL, Semaglutide is a medication that works as a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps regulate blood sugar levels.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Novo Nordisk A/S is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Semaglutide N |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes (PHASE4)
- Bariatric Surgery Combined With GLP-1 Receptor Agonists Study (PHASE1, PHASE2)
- Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome (PHASE4)
- A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV (PHASE1)
- Semaglutide for Helping Opioid Recovery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Semaglutide N CI brief — competitive landscape report
- Semaglutide N updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI
Frequently asked questions about Semaglutide N
What is Semaglutide N?
Who makes Semaglutide N?
What development phase is Semaglutide N in?
Related
- Manufacturer: Novo Nordisk A/S — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing